U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07459543) titled 'A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India' on March 05.
Brief Summary: The purpose of this study is to assess the safety and tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in untreated, unresectable or metastatic melanoma participants in India
Study Start Date: Nov. 15, 2026
Study Type: INTERVENTIONAL
Condition:
Untreated Melanoma
Unresectable Melanoma
Metastatic Melanoma
Intervention:
DRUG: Nivolumab + Relatlimab
Specified dose on specified days
Recruitment Status: NOT_YET...